Vivos Therapeutics, Inc. (VVOS)

NCM – Real Time Price. Currency in USD

0.73

+0.03 (4.85%)

At close: May 12, 2026, 4:00 PM EDT

0.74

+0.01 (1.79%)

Pre-market: May 13, 2026, 8:06 AM EDT

09.05.2026

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.

15.04.2026

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript

15.04.2026

Vivos Therapeutics Reports Full Year 2025 Financial Results

Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the full year ended December 31, 2025.

15.04.2026

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026.

07.04.2026

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced that it has closed on a private placement with V-Co Investors 3 LLC (“V-Co 3”), an affiliate of New Seneca Partners Inc. (“Seneca”).

26.03.2026

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare

17.03.2026

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children.

Videos

No Data

There is no data to display

Press releases

15.04.2026

Vivos Therapeutics Reports Full Year 2025 Financial Results

07.04.2026

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

26.03.2026

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare

17.03.2026

Vivos Therapeutics, Inc. (VVOS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vivos Therapeutics, Inc. (VVOS)

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Videos

No Data

Press releases

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Videos

No Data

Press releases

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Search stocks

Vivos Therapeutics, Inc. (VVOS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vivos Therapeutics, Inc. (VVOS)

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Videos

No Data

Press releases

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Videos

No Data

Press releases

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy